Preventing mouth problems from GPRC5D therapy in myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a preventive treatment for mouth or taste problems that can be caused by a newer type of multiple myeloma therapy. It aims to help people who have already tried several standard treatments and whose disease is still active.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has gotten worse after your last treatment.
- You have already tried at least three types of myeloma treatments (including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody).
- You are in fairly good health (able to do light work or better) or have stable physical limitations (like using a wheelchair) that aren't caused by your myeloma.
- You do not have severe or ongoing taste problems, mouth infections, or mouth sores that could interfere with the study.
- You have not had a stroke, heart attack, or major blood clot in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug ramantamig to standard treatments (daratumumab, bortezomib, lenalidomide, and dexamethasone) works better for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares three treatment groups to find the safest and most effective option.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.